gblx20230629_nt10k.htm

0001437749-23-018963.txt : 20230630 0001437749-23-018963.hdr.sgml : 20230630 20230630080024 ACCESSION NUMBER: 0001437749-23-018963 CONFORMED SUBMISSION TYPE: NT 10-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230630 DATE AS OF CHANGE: 20230630 EFFECTIVENESS DATE: 20230630 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GB SCIENCES INC CENTRAL INDEX KEY: 0001165320 STANDARD INDUSTRIAL CLASSIFICATION: CRUDE PETROLEUM & NATURAL GAS [1311] IRS NUMBER: 593733133 STATE OF INCORPORATION: NV FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: NT 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-55462 FILM NUMBER: 231059478 BUSINESS ADDRESS: STREET 1: 6450 CAMERON STREET #110A CITY: LAS VEGAS STATE: NV ZIP: 89118 BUSINESS PHONE: (844) 843-2569 MAIL ADDRESS: STREET 1: 6450 CAMERON STREET #110A CITY: LAS VEGAS STATE: NV ZIP: 89118 FORMER COMPANY: FORMER CONFORMED NAME: Growblox Sciences, Inc. DATE OF NAME CHANGE: 20140603 FORMER COMPANY: FORMER CONFORMED NAME: Signature Exploration & Production Corp. DATE OF NAME CHANGE: 20080602 FORMER COMPANY: FORMER CONFORMED NAME: Diabetic Treatment Centers of America, Inc. DATE OF NAME CHANGE: 20040812 NT 10-K 1 gblx20230629_nt10k.htm FORM NT 10-K gblx20230629_nt10k.htm

SEC File Number: 000-55462

CUSIP Number: 361544109

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 12b-25

Notification of Late Filing

(Check One):

☒ Form 10-K☐ Form 20-F☐ Form 11-K ☐ Form 10-Q☐ Form 10-D

☐ Form N-SAR☐ Form N-CSR

For Period Ended: March 31, 2023

☐Transition Report on Form 10-K

☐Transition Report on Form 20-F

☐Transition Report on Form 11-K

☐Transition Report on Form 10-Q

☐Transition Report on Form N-SAR

For the Transition Period Ended: _______________________

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

Part I - Registrant Information

GB Sciences, Inc.

Full Name of Registrant

N/A

Former Name if Applicable

9205 W. Russell Road, Suite 240

Address of Principal Executive Office (Street and Number)

Las Vegas, Nevada 89148

City, State and Zip Code

Part II - Rules 12b-25(b) and (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box, if appropriate)

☒(a)The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

☒(b)The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N- SAR, or Form N-CSR, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and

☐(c)The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

Part III - Narrative

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof could not be filed within the prescribed period.

GB Sciences, Inc. (the “Company”) has determined that it is unable to file its Annual Report on Form 10-K for the fiscal year ending March 31, 2023, within the prescribed time period without unreasonable effort or expense. Zach Swarts, our longtime CFO was hired away from the Company on April 14, 2023. The need for replacement accounting personnel to have time to learn about the Company and produce the Form 10-K has resulted in the Company not being able to compile and file the Form 10-K within the customary time period.

Part IV - Other Information

(1)Name and telephone number of the person to contract in regard to this notification.

Gary R. Henrie		(307)		200-9415
(Name)		(Area Code)		(Telephone Number)

(2)Have all other periodic reports required under section 13 or 15(d) of the Securities Exchange Act of 1934 or section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

☒ Yes ☐ No

(3)Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

☐ Yes ☒ No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

GB Sciences, Inc.

(Name of Registrant as specified in charter)

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

Date: June 30, 2023	By:/s/ John Poss
	John Poss, Chief Executive Officer

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

Intentional misstatements or omissions of fact constitute federal criminal violations (See 18 U.S.C. 1001).